#United States #Atlanta #Colorectal Cancer #American Cancer Society #Screening Guidelines

Major Update on Colorectal Cancer Screening Guidelines by ACS

The American Cancer Society (ACS) has unveiled its revised guidelines for colorectal cancer screening, marking a significant change in how screening will be conducted for average-risk adults. The new recommendations advocate for screening to begin at age 45 and to continue for individuals up to 75 years old, as long as their life expectancy exceeds ten years. This pivotal shift aims to enhance early detection and encourage higher participation rates, especially since studies have shown that timely screening can lead to five-year survival rates exceeding 90% when cancer is detected in its early stages.

Key Changes in Screening Procedures

One of the most noteworthy changes is the introduction of new screening options, including a blood-based test and updated at-home stool tests. Dr. Robert Smith, the senior vice president of early cancer detection science at ACS, underscores the importance of making colorectal cancer screening more accessible. "We need to stress that colorectal cancer is as preventable as it is treatable. By expanding our screening options, we aim to ensure that more eligible adults can engage in lifesaving testing, thereby bridging the existing screening gap," he states.

The updates include a mix of procedures, focusing on both convenience and effectiveness:

1. At-Home Stool Testing: Two main tests are now included:
- Next Generation Multi-Target Stool DNA Test (Cologuard): An enhancement of the previously recommended at-home test that analyzes stool for specific DNA markers and hemoglobin.
- New Multi-Target Stool RNA Test (ColoSense): This is a new home testing kit that identifies stool-based RNA markers along with hemoglobin, showing promise for high sensitivity in detecting colorectal cancer.

These home tests offer screening every three years, providing a less invasive alternative for those who may hesitate to undergo traditional methods.

2. Blood-Based Testing: This option detects tumor DNA in a blood sample and is recommended primarily for individuals who opt out of or cannot complete the preferred screening options. It's important to note that while these tests are innovative, their sensitivity for precancerous conditions and early-stage cancers is lower than established stool tests.

Each positive stool or blood test result will necessitate a follow-up colonoscopy within six months to confirm results and complete the screening process effectively.

Traditional Screening Methods Remain

Despite the introduction of new screening options, foundational methods continue to play a significant role:

• - High-sensitivity guaiac-based fecal occult blood tests (gFOBT) and high-sensitivity fecal immunochemical tests (FIT) continue to be recommended annually.
• - Colonoscopies remain the gold standard, with scheduling once every ten years, while flexible sigmoidoscopy and CT colonography are available every five years.

Individuals with an increased or high risk of colorectal cancer may need to begin screenings earlier than 45 and may be required to get screened more frequently.

Addressing Access and Equity

A critical aspect of these updates is the ACS’s commitment to equity in healthcare. Dr. William Dahut, the organization’s chief scientific officer, emphasizes the need for increased screening among underserved and rural populations. "These changes are designed to broaden the screening arsenal, ensuring preventive cancer care reaches all demographics effectively."

The American Cancer Society Cancer Action Network (ACS CAN) is actively involved in advocating for policies at various government levels to support accessible screening. ACS CAN President Lisa A. Lacasse elaborates, stating that access to coverage and affordability remains a major challenge for many eligible individuals. They are dedicated to lobbying for policies that minimize or eliminate out-of-pocket costs associated with screening.

Conclusion: The Importance of Screening

The revised screening guidelines not only reflect advances in medical science but also aim to address significant public health challenges. The ultimate goal is to lower the incidence of colorectal cancer through improved access and innovative testing options.

With colorectal cancer ranking as the leading cause of cancer-related deaths among adults under 50, increasing screening compliance is more critical than ever. The ACS's new guidelines underscore the importance of regular screenings and the proactive steps taken to save lives across various communities.

For further information on colorectal cancer, statistics, and resources, visit the American Cancer Society’s website or call their 24/7 helpline.